• Home
    • Overview/Our mission
    • News and Events
    • Stock Quote
  • About us
    • At a glance
    • Our values
    • Management team
    • Board of Directors
    • Scientific Advisors
      • Cell Therapy Scientific Advisory Board
      • Glioblastoma Scientific Advisory Board
  • Science
    • NK Cell Derived Allogeneic Therapies
      • CHM 0201 (CORE-NK Platform)
      • CHM 0301 (Next Generation CORE-NK Platform)
      • CHM 1301 (CLTX CAR-NK)
      • CHM 2301 (CDH17 CAR-NK)
      • CHM 3301 (Undisclosed CAR-NK)
    • T Cell Derived Autologous Therapies
      • CHM 1101 (CLTX CAR T)
      • CHM 2101 (CDH17 CAR T)
    • Collaborations
    • About Cell Therapy
  • Pipeline
    • Overview
    • Clinical Trials
      • CHM 1101 (CLTX CAR T)
      • CHM 0201 (CORE-NK Platform)
    • Abstracts and Publications
  • News and Events
    • Press releases
    • Events and presentations
    • Media Coverage
    • Media Resources
  • Investors
    • Corporate Profile​
    • Investor News and Events
      • Annual Report
      • Press releases
      • Events and presentations
      • Analyst Coverage
      • Shareholder Newsletters
    • Stock information
      • Stock quote and chart
      • Historical price lookup
    • Corporate Governance
      • Corporate Charters
      • Corporate Policies
    • Resources
      • Investor Q and A
      • Email alerts
      • Investor Contacts
  • Careers
Menu
  • Home
    • Overview/Our mission
    • News and Events
    • Stock Quote
  • About us
    • At a glance
    • Our values
    • Management team
    • Board of Directors
    • Scientific Advisors
      • Cell Therapy Scientific Advisory Board
      • Glioblastoma Scientific Advisory Board
  • Science
    • NK Cell Derived Allogeneic Therapies
      • CHM 0201 (CORE-NK Platform)
      • CHM 0301 (Next Generation CORE-NK Platform)
      • CHM 1301 (CLTX CAR-NK)
      • CHM 2301 (CDH17 CAR-NK)
      • CHM 3301 (Undisclosed CAR-NK)
    • T Cell Derived Autologous Therapies
      • CHM 1101 (CLTX CAR T)
      • CHM 2101 (CDH17 CAR T)
    • Collaborations
    • About Cell Therapy
  • Pipeline
    • Overview
    • Clinical Trials
      • CHM 1101 (CLTX CAR T)
      • CHM 0201 (CORE-NK Platform)
    • Abstracts and Publications
  • News and Events
    • Press releases
    • Events and presentations
    • Media Coverage
    • Media Resources
  • Investors
    • Corporate Profile​
    • Investor News and Events
      • Annual Report
      • Press releases
      • Events and presentations
      • Analyst Coverage
      • Shareholder Newsletters
    • Stock information
      • Stock quote and chart
      • Historical price lookup
    • Corporate Governance
      • Corporate Charters
      • Corporate Policies
    • Resources
      • Investor Q and A
      • Email alerts
      • Investor Contacts
  • Careers
Linkedin-in Youtube Twitter Envelope
Events and Presentations

On The Bid – Stockhead video series – CAR T therapy edition featuring CHM CEO Jenn Chow

Read More »
October 2022
Events and Presentations

ASX Small and Mid Cap Conference – Jennifer Chow CEO 23 Sep 2022

Read More »
September 2022
Events and Presentations

CHM 1101 (CLTX CAR T) Presents Positive Initial Phase 1 Clinical Data

Read More »
November 2021
Events and Presentations

CHM 1101 (CLTX CAR T) Phase 1 Initial Data Release Presentation

Read More »
November 2021
Events and Presentations

CEO Jennifer Chow’s presentation at AusBiotech Conference 2021

Read More »
October 2021
Events and Presentations

CHM Virtual User Meeting Guide 2021

Read More »
October 2021
Events and Presentations

CHM Notice of 2021 AGM & Proxy Form

Read More »
October 2021
Events and Presentations

ASX Small and Mid Cap Conference – Jennifer Chow, Chimeric CEO – Tuesday, September 14

Read More »
September 2021
Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference – Sep 13, 2021 at 7:30 AM EDT (presentation materials and associated webcasts will be posted on the company’s website on September 13)

Read More »
September 2021
Events and Presentations

Corporate Presentation: Exclusive Licensing of CDH17 CAR T Cell Therapy from the University of Pennsylvania

Read More »
July 2021
Page1 Page2
Sign-up to our mailing list to receive all the latest news from Chimeric Therapeutics
 
Please fill out our form for Investor Relations Inquiries
Investor Contacts
Linkedin-in Youtube Twitter Envelope